01 feb: Alm. Brand A/S – Økonomidirektør skifter til nyt job
01 feb: Coloplast leverer tilfredsstillende kvartalsregnskab på linje med..
01-02-2017 12:00:00

Announcement no. 1 - Interim Financial Report, Q1 2016/17

Relateret indhold
24 maj - 
Coloplast: Bestyrelsesmedlem køber aktier for 30 mio. k..
23 maj - 
Tirsdagens aktier: Topdanmark stjal scenen på stille da..
08 maj - 
Aktier/tendens: Investorernes begejstring over Vestas k..

Highlights

·       Organic revenue growth was 6%. Revenue in DKK was up by 3% to DKK 3,755m.

·       Organic growth rates by business area: Ostomy Care 6%, Continence Care 5%, Urology Care 8% and Wound & Skin Care 5%.

·       As expected, growth in the US Chronic Care business was adversely affected by inventory reductions at large distributors, and inventory levels are now back to normal.

·       The South Korean healthcare authorities have enhanced subsidy schemes for intermittent catheters effective 1 January 2017 to cover approximately 25,000 South Koreans.

·       The acquisition of US distributor Comfort Medical was approved at the end of December at a value of DKK 1.1bn.

·       Management estimates that more than 95% of the lawsuits in the US alleging injury resulting from the use of transvaginal surgical mesh products designed to treat pelvic organ prolapse and stress urinary incontinence have been settled at the date of this report.

·       EBIT was up by 3% measured in DKK and 8% at constant exchange rates, to DKK 1,226m. The EBIT margin was 33% at constant exchange rates, against 32% last year. Measured in DKK, the EBIT margin was 33%, which was in line with the year-earlier period.

·       The net profit for the reporting period was up by 15% to DKK 946m, while diluted earnings per share were also up by 15% to DKK 4.46.

·       The free cash flow was negative at DKK 833m, DKK 1,664m less than in the same period of last year. Adjusted for payments made in connection with lawsuits alleging injury resulting from the use of transvaginal surgical mesh products and the acquisition of Comfort Medical, the free cash flow was an inflow of DKK 1,439m against DKK 1,284m in Q1 2015/16.

·       The second part of the share buy-back programme totalling DKK 1bn running until the end of the 2016/17 financial year is expected to be launched in Q2 2016/17.

 

Financial guidance for 2016/17

·       We expect revenue growth of 7-8% at constant exchange rates and of 7-8% in DKK.

·       We expect an EBIT margin of 33-34%, at constant exchange rates and of about 33% in DKK.

·       Capital expenditure is expected to be about DKK 700m.

·       The effective tax rate is expected to be about 23%.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

24 maj E:COLOB
24 maj E:COLOB
24 maj E:COLOB
24 maj E:COLOB
23 maj E:COLOB
23 maj E:COLOB
23 maj E:COLOB
23 maj E:COLOB

Dong-topchef om salg af oliedivision: Den samlede pris er rigtig fin

24-05-2017 16:33:25
Flere iagttagere har kaldt salgsprisen for Dongs olie- og gasforretning lav, men hos energiselskabet selv mener man, at prisen er rigtig god, når man ser på det samlede regnestykke.Sådan lyder det fra Dongs administrerende direktør, Henrik Poulsen, efter at selskabet onsdag har gjort klar til et salg til den britiske kemikoncern Ineos.- Vi har fået en rigtig fin pris for forretningen. Vi har fået ..

Nordex-Acciona/dir: Har rigtig godt momentum i USA

24-05-2017 12:06:06
Den tyske vindmølleproducent Nordex, der for nylig overtog Acciona Windpower, har USA som et af nøglemarkederne, hvor selskabet venter at kunne fortsætte væksten fra et travlt 2017.- Vi har et rigtigt godt momentum i markedet, og i år kommer vil til at installere tæt ved 800 megawatt i USA siger Thomas Donoghue, som er salgschef for Nordex-Acciona på det nordamerikanske marked, til Ritzau Finans p..

Aktier/åbning: Salg af oliebiks sender Dong op i lyserødt marked

24-05-2017 09:07:05
Lige da alt så ud til at være ganske fredeligt før åbningen af det danske aktiemarked onsdag før den lange weekend, strøg Dong i fokus med nyheden om, at olie- og gasforretningen bliver solgt til kemivirksomheden Ineos.Dong satte forretningsdelen til salg i efteråret, og Dong har selv flere gange sagt, at et frasalg var ventet i løbet af 2017. Prisen kan løbe op i 8,7 mia. kr. og ændrer ikke ved 2..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Coloplast 83,85 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
29. maj 2017 02:05:31
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170517.1 - EUROWEB7 - 2017-05-29 02:05:31 - 2017-05-29 02:05:31 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x